This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. 2.1 The Primary Aim WARCEF is a two-arm (1:1) double-blind randomized multicenter clinical trial. Its primary aim is to compare the effectiveness of warfarin and aspirin therapies in heart failure patients, while taking account of risk of hemorrhage. The primary null hypothesis is that in patients with EF ? 35%, there is no difference between warfarin (INR 2.5-3.0 with a target INR of 2.75) and aspirin (325 mg/day) therapies in time to the first to occur of ischemic stroke, intracerebral hemorrhage (ICH), or death. This is tested against the alternative hypothesis of a non-zero difference between these two therapies, at a = .05 two- sided, with power of 80% to detect a 17.82% hazard rate reduction (after appropriate allowance for crossover and loss to follow-up), with symmetrical stopping and decision rules. 3201 patients with 2-6 years of follow-up are required. Any of the three possible outcomes will be clinically important: + If warfarin is better, use of warfarin will be recommended. + If aspirin is better, use of aspirin will be recommended. + If the evidence is insufficient to declare either better, use of aspirin will be recommended, given its lower cost and easier administration. WARCEF is thus expected to be clinically decisive if it is completed with satisfactory power. 2.2 The Secondary Aims 1 The main secondary aim is to test the hypothesis of no difference in warfarin and aspirin therapies in time to the first to occur of, ischemic stroke, ICH, myocardial infarction (MI), heart failure (HF) hospitalization, or death. The additional secondary aims are to answer these questions: 2 Is warfarin or aspirin superior for reducing stroke (ischemic and hemorrhagic)? 3 Among women, is warfarin or aspirin therapy superior for reducing ischemic stroke, ICH, MI, heart failure hospitalization, or death? 4 Among African-Americans, is warfarin or aspirin therapy superior for reducing ischemic stroke, ICH, MI, heart failure hospitalization or death? 5 Does any relative risk or benefit of warfarin or aspirin for stroke, transient ischemic attack (TIA), or peripheral embolism depend on ejection fraction? 6 Does any relative risk or benefit of warfarin or aspirin depend on heart failure class (NYHA class)? 7 Does any relative risk or benefit of warfarin or aspirin depend on etiology of cardiac failure? 8 Do warfarin and aspirin differ in their effect on cognitive function? 9 Does warfarin have a larger risk reduction relative to aspirin in cardioembolic than other stroke subtypes? 10 Are cardioembolic infarcts more frequent in patients with non-ischemic than ischemic cardiac disease? 11 Are cardioembolic infarcts more frequent in women than in men? 12 Is mean cerebral infarct volume greater in patients with EF ? 20% than in patients with EF 20%? 2.3 The Tertiary aim is to combine the WARCEF data with that of the Warfarin Antiplatelet Trial in Chronic Heart Failure (WATCH) to provide more statistical power to address the secondary aims 1 through 7.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54RR026137-03
Application #
8359895
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
2011-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
3
Fiscal Year
2011
Total Cost
$83,146
Indirect Cost
Name
Morehouse School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
102005451
City
Atlanta
State
GA
Country
United States
Zip Code
30310
Sánchez-Bretaño, Aída; Baba, Kenkichi; Janjua, Uzair et al. (2017) Melatonin partially protects 661W cells from H2O2-induced death by inhibiting Fas/FasL-caspase-3. Mol Vis 23:844-852
Laurent, Virgine; Sengupta, Anamika; Sánchez-Bretaño, Aída et al. (2017) Melatonin signaling affects the timing in the daily rhythm of phagocytic activity by the retinal pigment epithelium. Exp Eye Res 165:90-95
Simmons, Lauren J; Surles-Zeigler, Monique C; Li, Yonggang et al. (2016) Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway. J Neuroinflammation 13:237
Jockers, Ralf; Delagrange, Philippe; Dubocovich, Margarita L et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 173:2702-25
Gianesini, Coralie; Hiragaki, Susumu; Laurent, Virginie et al. (2016) Cone Viability Is Affected by Disruption of Melatonin Receptors Signaling. Invest Ophthalmol Vis Sci 57:94-104
White, Todd E; Surles-Zeigler, Monique C; Ford, Gregory D et al. (2016) Bilateral gene interaction hierarchy analysis of the cell death gene response emphasizes the significance of cell cycle genes following unilateral traumatic brain injury. BMC Genomics 17:130
Zhang, Yuanyuan; George, Jasmine; Li, Yun et al. (2015) Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker diabetic Fatty rats and is induced by albumin in in vitro primary parietal cell culture. PLoS One 10:e0123276
Hyacinth, Hyacinth I; Adams, Robert J; Greenberg, Charles S et al. (2015) Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke. PLoS One 10:e0134193
Li, Yonggang; Lein, Pamela J; Ford, Gregory D et al. (2015) Neuregulin-1 inhibits neuroinflammatory responses in a rat model of organophosphate-nerve agent-induced delayed neuronal injury. J Neuroinflammation 12:64
Rust, George; Zhang, Shun; Holloway, Kelvin et al. (2015) Timing of emergency department visits for childhood asthma after initial inhaled corticosteroid use. Popul Health Manag 18:54-60

Showing the most recent 10 out of 65 publications